8226; Hit Finding and Lead Generation. We anticipate giving an initial clinical update on this trial in the second half of 2021. We believe our Dynamo platform has the potential to address many of these targets. This results in decreased efficacy by requiring dose reductions. RLY-4008 showed greater than 200-fold selectivity for FGFR2 over FGFR1. Another predicted advantage of RLY-4008 concerns resistance mutations. Heatmap showing fold change in potency (IC50) on FGFR2 mutations compared to FGFR2 WT. Patients will initially receive RLY-4008 administered orally, twice daily. The abbreviation "H1047X" is used to refer to any H1047 mutation. Biochemical potency for RLY-PI3K1047 compared to alpelisib and GDC-0077. All samples were run in duplicate and data represent the mean. The selectivity of RTX-1 was then evaluated in vivo. This is generally referred to as bypass resistance. DNA sequencing did not reveal new ALK mutations in the cell line. Each animal is represented as a separate bar 37 & (number of mice per group = 9). Through an affiliate, D. E. Shaw Research is also one of our investors. We also have other collaborations mostly focused on developing machine learning models. These exclusivity restrictions do not extend past the initial research term. FDA must approve an NDA before a drug may be marketed in the United States. These rules (with exceptions) became effective January 19, 2021. This final rule codified CMS's policy change that was effective January 1, 2019. The Interim Final Rule has not been finalized and is subject to revision and challenge. The market implications of the final rule and guidance are unknown at this time. For example, we may experience manufacturing delays with IND-enabling studies. A failure of one or more clinical trials 67 & can occur at any stage of testing. Collaborations are complex and time-consuming to negotiate and document. We commenced operations in May 2015. If these collaborations are not successful, our business could be adversely affected." We also have the implicit right to defend patents that cover work product owned by us. Designation as a breakthrough therapy is within the discretion of the FDA. It is impossible to determine whether similar taxes could be instated in the future. The market price of our common stock may be volatile.